Getting latest data loading
Home / Morning Report / Morning Report – 19th December 2022

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 19 December 2022

Yesterday’s UK 100 Leaders Price (p) % Chg
Standard Chartered plc 612.8 1.4%
Fresnillo 857.4 0.5%
BAE Systems plc 839.8 0.3%
Glencore plc 533.5 0.2%
British American Tobacco plc 3,287.8 0.1%
Yesterday’s UK 100 Laggards Price (p) % Chg
Unite Group 888.3 -5.1%
Segro Plc 754.8 -5.1%
Intermediate Capital Group plc 1,136.5 -5.1%
Land Securities Group plc 607.8 -4.9%
Ocado Group plc 628.2 -4.8%

 

Major World Indices Price % Chg 1 YEAR
UK 100 INDEX 7,311 -1.6% 0.8%
DOW JONES INDUS. AVG 32,828 -1.1% -8.6%
DAX INDEX 13,849 -1.0% -11.2%
NIKKEI 225 27,527 -1.9% -5.3%
S&P/ASX 200 INDEX 7,149 -0.8% -2.1%
Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 74.23 -2.47%
Brent Crude (ICE) USD/bbl. 79.16 -2.52%
Gold Spot USD/t oz. 1,788 0.6%
Copper (Comex) USd/lb. 377 0.1%
The UK 100 is called to open +26 points this morning at 7358.  

4 hours; 8 Months

Click graph to enlarge

Markets Overview:

The UK 100 is called to open +26 points this morning at 7358.  The UK 100 looks set to make a bright start to trading on Monday recouping some of last week’s falls and despite weakness in Asian markets.  On Friday, The Dow Jones lost 281.76 points, or 0.85%, to 32,920.46. The S&P fell 1.11% to 3,852.36. Meanwhile, the tech-heavy Nasdaq declined 0.97% to 10,705.41.

 

 

Company News & Broker Comments:

Company News:

AstraZeneca's Phase III trial for AstraZeneca's Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoints of improving overall survival.

 

 

AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union (EU) for advanced liver and lung cancers.

Ferguson plc announces that, in continuation of its $2.5 billion share repurchase program it has entered into an irrevocable and non-discretionary arrangement with its broker Barclays Capital Securities Limited and Barclays Capital Inc. Commencing from December 19, 2022 and ending no later than January 12, 2023. Under this arrangement, Barclays, an independent third party, will act as principal and will make decisions under the program independently from the Company.

 

 

Broker Comments:

 No New broker comments

Reporting Today:

None

 

Reporting Tuesday:

Petrofac

 

In Focus Today:

German IFO – Business Climate

 

EU Labor Cost

 

This Week's Ex-Dividends:

UK 100 companies going  ex-dividend on 22nd December 2022:

 

 

British American Tobacco

 

United Utilities Group

 

Halma

UK 250 companies going  ex-dividend on 22nd December 2022:

 

 

Home REIT

 

Britvic

 

IntegraFin Holdings

 

JPMorgan Japanese Investment Trust

 

Law Debenture Corporation

 

abrdn Private Equity Opportunities Trust

 

Mercantile Investment Trust

 

JPMorgan European Discovery Trust

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.